Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do germline genetic variants influence surgical outcomes in drug-resistant epilepsy?

Epilepsy research·2024
Same author

A data-driven quality-score system for rating drug products and its implications for the health care industry.

Journal of the American Pharmacists Association : JAPhA·2022
Same author

EEG Abnormalities and Their Radiographic Correlates in a COVID-19 Inpatient Cohort.

Neurology. Clinical practice·2022
Same author

Tracking Multisite Seizure Propagation Using Ictal High-Gamma Activity.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2021
Same author

Obstructive Sleep Apnea: Cognitive Outcomes.

Clinics in geriatric medicine·2021
Same author

Proceedings of the Sleep and Epilepsy Workshop: Section 1 Decreasing Seizures-Improving Sleep and Seizures, Themes for Future Research.

Epilepsy currents·2021

Related Experiment Video

Updated: Jun 12, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Update on anticonvulsant drugs.

Derek J Chong1, Carl W Bazil

  • 1Columbia Comprehensive Epilepsy Center, Department of Neurology, Columbia University, 710 West 168th Street, 7th Floor, New York, NY 10032, USA. dc2223@mail.cumc.columbia.edu

Current Neurology and Neuroscience Reports
|May 22, 2010
PubMed
Summary

New epilepsy medications offer more treatment options but pose challenges. This review covers key issues like osteoporosis risk, pregnancy safety, generic equivalence, and suicidality associated with epilepsy drugs.

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Related Experiment Videos

Last Updated: Jun 12, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Epilepsy treatment has expanded with recent US FDA approvals of rufinamide, lacosamide, and vigabatrin.
  • Extended-release formulations of lamotrigine and levetiracetam also recently became available.
  • The growing number of epilepsy medications presents both expanded choices and challenges for clinical expertise.

Purpose of the Study:

  • To review recent advancements in epilepsy medication approvals.
  • To discuss critical issues surrounding epilepsy drug use, including osteoporosis, pregnancy safety, generic equivalence, and suicidality.
  • To provide an updated overview of medical management strategies for epilepsy.

Main Methods:

  • Literature review of recent epilepsy medication approvals and associated research.
  • Analysis of safety data concerning osteoporosis, pregnancy, and suicidality.
  • Evaluation of biological equivalence for generic epilepsy drug formulations.

Main Results:

  • Recent approvals have increased the therapeutic arsenal for epilepsy management.
  • Emerging concerns include potential links between epilepsy medications and osteoporosis, pregnancy risks, and suicidality.
  • Ensuring biological equivalence of generic versions remains an important consideration.

Conclusions:

  • The expanded options for epilepsy treatment require careful consideration of associated risks and benefits.
  • Ongoing research and clinical vigilance are essential for optimizing patient outcomes in epilepsy management.
  • This review offers a current perspective to aid practitioners in the medical management of epilepsy.